[ad_1]
MANHATTAN, New York, Jan. 11, 2022 (GLOBE NEWSWIRE) — Healixa, Inc. (OTC:Emmer) (“Healixa” or the “Company”), a technology company focused on building and acquiring innovative and disruptive technologies in the healthtech, clean water and greentech industries, announced today: Christopher Galliano Will join its board of directors (the “Board”) as a non-executive independent director, effective immediately, demonstrating the company’s focus on corporate governance, growth and national list requirements.
Mr. Galliano has extensive experience directing large-scale defense-related projects, including rapid prototyping, software engineering and modernization, legacy systems conversion, and systems engineering systems for urgent needs. Mr. Galliano currently serves as Chief Technology Officer and Co-Founder Tianshan Medical, where he co-authored more than 6 artificial intelligence (“AI”)-based drug discovery patents and led daily research to build oral therapeutics for COVID-19 and 12 other active invention/drug development.
Mr. Galliano’s previous accomplishments and projects include building NATO IT Modernization (“ITM”) work, the largest IT acquisition in NATO history and the Navy Enterprise Data Center (“NEDC”) Division and subsequent consolidation of over 100 data centers into 3 enterprises data center. As a former executive officer of Space and Naval Warfare Systems, Mr. Galliano led the program to modernize…
The full story is available on Benzinga.com
[ad_2]
Source link
